ArticleJournal of clinical biochemistry and nutrition2025
Influence of transarterial chemoembolization on serum opsonic activity in hepatocellular carcinoma measured by chemiluminescence.
Article in Journal of clinical biochemistry and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the physical stress associated with transarterial chemoembolization (TACE), a catheter-based treatment for hepatocellular carcinoma, by examining changes in serum opsonic activity (SOA). SOA was examined by measuring reactive oxygen species (ROS) produced by neutrophils using lucigenin-dependent chemiluminescence (LgCL) and luminol-dependent chemiluminescence (LmCL). Sixty-four patients were enrolled, and SOA was measured at admission, the following day, and 3 days after TACE. The area under the curve (AUC) for LgCL did not change significantly from baseline to the day after TACE but increased significantly from the following day to 3 days post-TACE. In contrast, no changes were observed in the AUC of LmCL. Subgroup analyses revealed a significant increase in LgCL from day 1 to day 3 post-TACE among patients aged >75 years, males, body mass index (BMI) <25 kg/m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.